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Abstract
Purpose To provide a complete evaluation of the long-term
impact of full-field digital mammography (FFDM) on the
improvement of early diagnosis in a population-based screen-
ing program.
Methods We included 82,961 screen-film mammograms
(SFM) and 79,031 FFDM from women aged 50–69 screened
biennially from 1995–2010 in Spain and followed-up to 2012.
The first screening round of the program was excluded. Rates
of cancer detection, interval cancer, tumoral characteristics
and other quality indicators were compared between SFM
and FFDM periods using the Chi-square test. Multivariate
logistic regression models were fitted.
Results Detection of ductal carcinoma in situ (DCIS) signifi-
cantly increased with FFDM (0.05 % vs 0.09 %; p=0.010),
along with the proportion of small invasive cancers (<20 mm)
(69.37 % vs 78.90 %; p=0.040). The false-positive rate de-
creased with FFDM (4.79 % vs 3.38 %; p<0.001) without
differences in the cancer detection rate (0.42 % vs 0.43 %;
p=0.685) or in the interval cancer rate (0.14 % vs 0.14 %;
p=0.816). Adjusted models showed a significant increase
in the detection of DCIS in the FFDM periods.
Conclusion Digitalization has supposed an improvement in
early diagnosis because DCIS and small invasive cancers
increased without a change in detection rate. Moreover,
false-positive reduction without an increase in the interval
cancer rate was confirmed.
Key Points
• Cancer detection did not increase after 6 years of digital
mammography
• Ductal carcinoma in situ rates remained higher throughout
the digital period
• The proportion of small invasive cancers was higher with
digital mammography
•We observed an improvement in early diagnosis with digital
mammography
• False-positive rates remained lower throughout the digital
period without interval cancer increase
Keywords Mass screening .Mammography . Diagnostic
imaging . Breast neoplasms . Carcinoma in situ
Abbreviations
DCIS Ductal carcinoma in situ
FFDM Full-field digital mammography
PPV Positive predictive value
SFM Screen film mammography
Introduction
The main goal of mammography screening is to reduce mor-
tality and morbidity from breast cancer through early detec-
tion. The diagnostic accuracy of full-field digital mammogra-
phy (FFDM) is clearly at least as good as that of screen-film
mammography (SFM) [1]. However, there are some contro-
versies on the specific effect on different performance indica-
tors, including the detection of ductal carcinoma in situ
(DCIS). Recent studies have shown that the detection rate is
higher with FFDM than with SFM, partly owing to greater
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detection of DCIS [2, 3]. Some studies providing data on the
characteristics of tumours detected by FFDMhave described a
trend to identify less advanced invasive cancers [2, 4]. These
results point to two possible situations: an improvement in
early diagnosis or, on the contrary, a worrying increase in
overdiagnosis. The effect of the switch to FFDM on recall
rate and positive predictive value (PPV) is unclear, with some
studies showing a higher recall rate and lower PPV [2, 5],
while others report a lower recall rate [6, 7] and similar or
higher PPV [8, 9]. The effect on interval cancer has been
studied less, but several reports have found no effect of FFDM
on interval cancer rate [6, 10, 11].
However, to our knowledge, no studies have presented data
on all these quality indicators together (cancer rates, including
interval cancer, sensitivity, specificity, PPV and tumour char-
acteristics). Moreover, one of the main limitations of studies
comparing the two technologies is the short time period since
the introduction of FFDM. Most of the studies provide data
only from the first one or two screening rounds performed
with FFDM [2, 5, 7–9, 12], which may have been influenced
by the transition from one technology to the other, as well as
by the learning curve. Therefore, the evolution of quality
indicators in subsequent digital screening rounds has scarcely
been evaluated. Evaluation of the long-term effect of FFDM
on the screening performance indicators within a cohort per-
spective is required for a complete evaluation of screening.
The aim of this study was to analyse trends in the cancer
detection rate (invasive cancers and DCIS), tumoral charac-
teristics, interval cancer rate and the sensitivity, specificity and
PPVof FFDM over a 16-year period with 6 years of complete
digitalization.
Patients and methods
Setting and study population
A retrospective cohort study was performed in women partic-
ipating in a population-based breast cancer screening program
in an area of 300,000 inhabitants in the city of Barcelona,
Spain. Women aged 50–69 years were invited by personal
letter to undergo mammography with a 2-year interval be-
tween screening rounds. We included data from 61,859 par-
ticipating women from 1 November 1995 to 31 December
2010, and followed up until 31December 2012. These women
were screened in two radiology units and underwent a total of
182,002 screens.
The two radiology units began screening activities with
SFM (SSH 140 A; Toshiba and Bennett, Trex Medical,
Copiague, NY. Film: Mamoray-HT, AGFA, Greenville, SC)
in 1995 and 1999, respectively, and shifted to FFDM (DM
1000 Agfa; Lorad, Danbury, Conn) in 2007 and 2004, respec-
tively. Mediolateral oblique and craniocaudal views were
available for each breast. All mammograms were read by
two radiologists using the BI-RADS classification [13], and
when double reading led to different assessments, a third
radiologist served as a tiebreaker. Prior screening mammo-
grams were always available in the original format during
reading in successive screenings.
The program was based on the European Guidelines for
Quality Assurance in Mammographic Screening [14] and its
results met the Europe Against Cancer standards. The study
was approved by the Ethics Committee of Parc de Salut Mar.
Informed consent was not required.
Screening procedures
The screening program keeps mammogram registers with data
from participants and the final outcome of screening. Two
results of a screening test are possible: normal findings (for
which screening mammography at 2 years is recommended)
and abnormal findings, which require further assessments to
confirm or exclude malignancy. When, after further assess-
ments, a tumour is found (DCIS or invasive cancer), the result
is considered a true positive. Otherwise, the result is consid-
ered a false positive.
Further assessments can include noninvasive procedures
(additional mammography, ultrasound, magnetic resonance
imaging) and/or invasive procedures (fine-needle aspiration,
core-needle biopsy, open biopsy). Once a malignant tumour is
histologically confirmed, the woman is sent to the referral
hospital for treatment and follow-up. These women are not
invited to further screening.
After a negative result of a screening episode, with
or without further assessments, and before the next
screening invitation, a woman may be diagnosed with
interval breast cancer [14]. Interval cancers were identi-
fied by merging data from the register of the screening
program with data from the hospital-based cancer regis-
try and telephone contact with women who underwent
mammography in the last scheduled screening but who
did not attend the following screening invitation. This
procedure covered 98 % of women lost to follow-up
from the program [15]. In our study, we extended the
definition of interval cancer until the 30th month, be-
cause each screening round can last up to 6 months. All
data sources kept information on the date of diagnosis,
which allowed us to ensure that all interval cancers
fitted the case definition.
This study included 161,992 screening mammograms per-
formed from the second screening round onwards (82,961
SFM and 79,031 FFDM). In all, 684 tumours were detected
in screening (345 with SFM and 339 with FFDM), and 226
tumours were diagnosed as interval cancers (114 with SFM
and 112 with FFDM) (Fig. 1).
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Study period
For the purpose of this study, the first screening round after the
implementation of the screening program in both radiology
units (RU1 and RU2) (prevalent round, all performed with
SFM) was excluded from the analyses. We excluded the first
round of the screening program because of its particular char-
acteristics, such as the prevalence peak of cancer detection and
the higher proportion of larger tumours, which could bias our
results. Thus, we excluded all screening mammograms per-
formed from November 1995 to December 1997 for RU1 and
from January 1999 to December 2000 in RU2 (n=20,010).
Overall, 9 years were covered by SFM (from January 1998 to
March 2007—9 years—in RU1, and from January 2001 to
September 2004—3 years—in RU2). Similarly, the digital
period covered 6 years (from March 2007 to December
2010—3 years—in RU1, and from September 2004 to Decem-
ber 2010 in RU2—6 years). Both radiology units cover two
closed neighbourhoods in Barcelona and use the same screening
protocol. Themammogramswere read by the same radiologists.
Study variables
Information from screening (initial or successive screening,
date of screening mammogram, further assessments, the use
of SFM or FFDM, and the final outcome of screening) was
obtained from the screening program database.
Age at diagnosis was obtained from the date of birth and
date of the screening mammogram.
Tumour-related information (invasiveness, pathological tu-
mour–node–metastasis [TNM] status and histological grade)
was drawn from the hospital-based cancer registry.
Statistical analyses
Cancer detection rates (overall, invasive and DCIS) were
computed as the number of cancers detected per 100 screening
tests performed with SFM and FFDM. To calculate the inter-
val cancer rate, women with cancer diagnosed at screening
were excluded from the denominator, because they were not
“at risk” of an interval cancer. Recall rate was defined as the
percentage of screened women requiring at least one further
assessment after a positive mammogram. False-positive rates
were defined as the number of further assessments (including
noninvasive and/or invasive procedures) with no cancer diag-
nosis divided by the number of screening tests, performed
with SFM and FFDM.
To calculate the accuracymeasures, we used the definitions
from the European Guidelines for Quality Assurance in Mam-
mographic Screening [14]. Sensitivity was computed as the
Fig. 1 Flow chart of the study.
Parc de Salut Mar breast cancer
screening program, Barcelona,
1995–2010
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proportion of cancers identified at screening (screen-detected
cancers) divided by the sum of screen-detected cancers and
interval cancers. Specificity was the proportion of truly nega-
tive screening examinations relative to true negatives plus
false positives. The PPV of the screening test was computed
as the proportion of screen-detected cancers divided by the
sum of false positives and screen-detected cancers. Propor-
tions were compared by the two-sided Chi-square test.
We computed a time/technique variable, which allowed us
to exclude possible confounding due to time trends and to
analyse information from the two radiology units together,
because they covered different periods using SFM and FFDM
[4, 7]. We divided the screening history in each radiology unit
into four equal time intervals (quartiles) both for the SFM
period and FFDM period. Therefore, each time interval for
SFM and DM had a similar number of screening tests.
Logistic regression analyses were performed to assess the
odds of cancer detection and interval cancer in the SFM and
FFDM periods, adjusting for radiology unit, age and whether
the diagnosis was established at the initial or successive
screenings. The logistic regression models were replicated to
assess the odds of invasive cancer and DCIS detection. For the
former, we censored DCIS diagnostics and for the latter, we
censored invasive diagnostics. Repeated measures in the lo-
gistic models were considered to be independent observations,
because cancer detection always depends on the absence of a
previous diagnosis. The outputs of the logistic regression
models were plotted, showing the adjusted odds ratios (OR)
and the 95 % confidence intervals (95 % CI).
We conducted a sensitivity analysis by including versus
excluding the 3-month learning period after the switch to
digital technology. We also compared the results by including
the program’s first screening round.
All p values were based on two-sided tests and were
considered statistically significant if less than 0.05. Statistical
analyses were performed using the SPSS (version 12.0).
Results
The overall cancer detection rate showed no statistically sig-
nificant differences between the SFM and FFDM periods
(0.42 vs 0.43 %; p=0.685, Table 1). However, the detection
rate of DCIS rose during the FFDM period (0.05 % vs 0.09%;
p=0.010), only in the initial screenings (0.06 % vs 0.12 %;
p=0.031). The rate of interval cancers showed no statistically
significant differences between the two study periods (0.14 %
vs. 0.14 %, respectively; p=0.816), whereas the rate of false
positives dramatically decreased during the FFDM period,
from 4.79 % to 3.38 % (p<0.001).
Table 2 shows tumour-related characteristics according to
whether cancers were detected by SFM or FFDM. Tumours
detected by FFDM tended to be diagnosed at earlier stages,
the proportion of DCIS being 20.30 % in FFDM and 13.14 %
in SFM (p=0.092). When invasive cancers only were consid-
ered, the proportion of cancers smaller than 20 mm was
significantly higher during the FFDM period than during the
SFM period (78.90 % vs. 69.37 %, respectively; p=0.040). In
DCIS, the percentage of high-grade tumours was higher in
those detected with FFDM than with SFM, although this
difference was not statistically significant (60.34 % vs.
51.22 %, respectively; p=0.581).
Figure 2 shows the distribution of tumour size of
invasive screen-detected cancers by study period. Dur-
ing the digital periods, the percentages of invasive can-
cers smaller than 20 mm tended to increase (73.1 % in
the 4th SFM period, and 80.3 in the 4th FFDM period;
p=0.095), whereas the proportion of T2 (tumours from
20 to 50 mm) became smaller in comparison with the
SFM periods (16.4 % in the 4th SFM period and
11.5 % in the 4th FFDM period; p=0.095).
Table 3 shows the rates of screen-detected cancers, interval
cancers, false positives, recall rate and accuracy measures
during the study period. The rate of screen-detected cancers
remained fairly stable across the study periods, with no par-
ticular trend. The interval cancer rate was 0.13 % in the first
SFM and increased to 0.21 % in the first FFDM period.
Thereafter, it gradually declined, reaching the lowest values
in the last FFDM period (0.11 %). The false-positive rate and
the recall rate showed a decreasing trend over time, especially
from the beginning of the digital period. Sensitivity, specificity
and PPV increased during the digital period.
Rates of screen-detected cancers, invasive cancer and
DCIS over time are shown in Fig. 3. Invasive cancer rates
slightly decreased in the last FFDM periods, while those of
DCIS increased over the same periods.
Figure 4 plots the adjusted OR for cancer detection at
screening (overall, invasive and DCIS) and for interval can-
cers. The introduction of FFDM did not increase cancer
detection at screening, although the risk increased in the 2nd
and 4th FFDM periods, without reaching statistical signifi-
cance [2nd DM period, OR=1.19 (95 % CI 0.88–1.62); 4th
FFDM period, OR=1.14 (95 % CI 0.84–1.55)]. The highest
detection of interval cancer was found in the first FFDM
period [OR=1.69 (95 %CI 1.03–2.77)] but the trend then
dramatically decreased over the subsequent FFDM periods.
In the FFDM periods, the risk of DCIS detection increased
significantly from an OR=1.58 (95 % CI 0.65–3.80) in the
first FFDM period to an OR=2.68 (95 % CI 1.19–6.00) in the
fourth DM period. Nevertheless, detection of invasive cancers
did not show a clearly declining pattern in the adjusted model.
The results of the sensitivity analysis revealed that inclu-
sion versus exclusion of the 3-month learning period after the
switch to digital technology did not significantly affect any of
the screening indicators presented. Equally, the inclusion of
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the first screening round did not modify the direction of our
findings.
Discussion
No differences were observed in overall cancer detection rates
between the SFM and FFDM periods. However, DCIS rates
increased with digital mammography, and remained higher
throughout the digital periods, while the invasive carcinoma
detection rate was somewhat lower in the FFDM periods.
Information on tumour characteristics pointed to a stage shift,
especially whenwe analysed the size of invasive tumours. The
proportion of smaller invasive tumours tended to increase
during the FFDMperiods. The proportion of high-grade DCIS
was also higher, but not statistically significant, in the
FFDM period. False-positive rates remained lower in all
the digital periods with no increase in the interval
cancer rate. No differences were observed in sensitivity
between the two periods, but specificity and especially
PPV increased throughout the FFDM periods. The ad-
justed screen-detected cancer (overall and invasive) and
interval cancer rates showed no statistically significant
differences throughout the study period, but detection of
DCIS increased in the FFDM period.
Most studies comparing the two technologies have detect-
ed an increase in DCIS detection rates with FFDM [2, 4, 6, 7,
9, 12]. In agreement with our results, the increase has been
observed especially in initial screenings [4, 7] but also in
successive ones [4, 7, 9]. The significance of this increase





b The total number of screened
women is not the sum of women
screened with screen-film and
full-field digital mammography,
because some women were
screened during both periods
(n=23,126)
c The interval cancer rate was cal-
culated as the number of interval
cancers over the number of
screened women minus women
with screen-detected cancer in
the same period
d Noninvasive and invasive
procedures
Screen-film mammography Digital mammography p valuea
n % n %
Screened womenb 39,182 43,406
Screening mammograms 82,961 79,031
Initial screening 21,187 14,532
Successive screening 61,774 64,499
Cancer detection rate 345 0.42 339 0.43 0.685
Initial screening 82 0.39 80 0.55 0.024
Successive screening 263 0.43 259 0.40 0.503
Invasive carcinomas detection rate 295 0.36 264 0.33 0.462
Initial screening 66 0.31 61 0.42 0.091
Successive screening 229 0.37 203 0.31 0.089
In situ carcinoma detection rate 45 0.05 70 0.09 0.010
Initial screening 12 0.06 18 0.12 0.031
Successive screening 33 0.05 52 0.08 0.063
Interval cancer ratec 114 0.14 112 0.14 0.816
Initial screening 39 0.18 32 0.22 0.447
Successive screening 75 0.12 80 0.12 0.895
Recall rate 4,628 5.57 3,316 4.20 <0.001
Initial screening 2,331 11.00 1,705 11.73 0.032
Successive screening 2,297 3.72 1,611 2.50 <0.001
False-positive for any proceduresd 3,970 4.79 2,675 3.38 <0.001
Initial screening 1,872 8.84 1,165 8.02 0.006
Successive screening 2,098 3.40 1,510 2.34 <0.001
Sensitivity 75.16 75.17 0.960
Initial screening 67.77 71.43 0.877
Successive screening 77.81 76.40 0.921
Specificity 95.19 96.60 0.040
Initial screening 91.11 91.92 0.578
Successive screening 96.59 97.65 0.175
Positive predictive value 8.00 11.25 <0.001
Initial screening 4.20 6.43 0.010
Successive screening 11.14 14.64 0.004
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on DCIS has been little studied and it is not known whether it
is due to earlier diagnosis [4, 6] or to overdiagnosis [2].
An earlier diagnosis should be followed by a decrease of
invasive cancers or at least by detection of less advanced
invasive cancers. Our results pointed to an earlier diagnosis,
showing not only significant differences in TNM stages, with
a higher proportion of DCIS in the FFDM period, but also a
higher proportion of smaller, invasive tumours along the
FFDM periods, which has also been reported by other authors
[6]. In line with our findings, recent work by Drukker et al.
reported a higher detection of biologically high-risk cancers
with FFDM [16]. Moreover, as previously reported [17],
among DCIS we found a higher proportion of high-grade
tumours in the FFDM period, although this difference was
Table 2 Tumour-related charac-
teristics of cancers detected by
screen-film mammography and
full-field digital mammography
a The number of in situ and inva-
sive carcinomas is not the sum of
overall cancers, because data are
missing on some tumours
(5 tumours in the SFM period
and 5 tumours in the FFDM
period)
b Tumours with missing informa-
tion were excluded from the cal-
culation of percentages
Screen-film mammography Digital mammography p value
n=340a % n=334a %
TNM stage
Stage 0 (in situ) 41 13.14 63 20.32
Stage I 156 50.00 157 50.65
Stage II 91 29.17 69 22.26
Stage III 21 6.73 19 6.13
Stage IV 3 0.96 2 0.65 0.092
Unknownb 28 24
TNM stage (invasive only)
Stage I 156 57.56 157 63.56
Stage II 91 33.58 69 27.90
Stage III 21 7.74 19 7.70
Stage IV 3 1.11 2 0.80 0.528
Unknownb 28 24
Tumour size (invasive only)
T1 (<20 mm) 188 69.37 194 78.90
T2 (20 to 50 mm) 58 21.40 32 13.00
T3 (>50 mm) 16 5.90 16 6.50
T4 9 3.32 4 1.60 0.040
Txb 28 24
Lymph node involvement (invasive only)
N0 197 72.70 181 73.28
N1–N3 74 27.30 66 26.72 0.959
Nxb 28 24
Metastasis (invasive only)
M0 268 98.90 245 99.59
M1 3 1.10 2 0.81 0.730
Mxb 28 24
Tumour grade
Ductal carcinoma in situ
I 8 19.51 11 18.97
II 12 29.27 12 20.69
III 21 51.22 35 60.34 0.581
Unknownb 4 12
Invasive cancers
I 86 36.91 95 43.78
II 102 43.78 68 31.34
III 45 19.31 54 24.88 0.023
Unknownb 62 47
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not statistically significant. Because low-grade DCIS may
have a lower potential to become invasive [18, 19], the similar
proportions observed in the two periods do not support the
hypothesis of overdiagnosis. However, larger series are nec-
essary to confirm this trend.
After the shift to FFDM, numerous studies in Spain [7, 20]
and elsewhere [21, 22] observed a reduction in the recall rate,
which led to suspicions of an increase in interval cancers and
false negatives. The current work, in agreement with previous
studies [6, 11], confirms that the reduction in recall rate was
not due to an increase in interval cancer during the FFDM
period. Although we have no information on interval cancer
subtypes, previously published data refute the hypothesis that
the introduction of FFDM has increased the number of false-
negative cancers [10, 11]. However, an increasing trend in the
detection of interval cancers was observed in the SFM pe-
riods, with the highest interval cancer rate in the first FFDM
period and a clear subsequent decrease. These increases could
be partly attributed to an improvement in the mechanisms to
detect interval cancers introduced in the screening programs
during their implementation (active follow-up of women,
merging data from the screening program registers with the
regional Minimum Basic Data Set—based on hospital dis-
charges with information on the principal diagnosis—and
Fig. 2 Distribution of tumour size of invasive screen-detected cancers by study periods





Interval cancers Recall rate False-positives Sensitivity Specificity Positive predictive
value
n % n % n % n %
1st SFM period 20,760 86 0.41 27 0.13 1,225 5.90 1,026 4.94 76.11 95.03 7.73
2nd SFM period 20,757 72 0.35 21 0.10 1,132 5.45 970 4.67 77.42 95.31 6.91
3rd SFM period 20,729 102 0.49 39 0.19 1,186 5.72 1,039 5.01 72.34 94.95 8.94
4th SFM period 20,714 85 0.41 27 0.13 1,084 5.23 934 4.51 75.89 95.47 8.34
1st FFDM period 19,733 81 0.41 42 0.21 815 4.13 678 3.44 65.85 96.54 10.67
2nd FFDM period 19,760 91 0.46 27 0.14 960 4.86 800 4.05 77.12 95.93 10.21
3rd FFDM period 19,780 80 0.40 22 0.11 750 3.79 594 3.00 78.43 96.98 11.87
4th FFDM period 19,701 87 0.44 21 0.11 788 4.00 600 3.05 80.56 96.94 12.66
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hospital-based cancer registries). However, after the shift to
FFDM, no further changes were made to those mechanisms.
Some studies have described a reduction in PPV after the
introduction of FFDM [2, 5], whereas others [4, 6–8, 12],
including ours, have shown an increase, especially in succes-
sive screenings. The implementation of digital technology in
our population-based screening program reduced the number
of adverse effects related to false-positive results and costs
[23], with similar cancer detection and interval cancer rates.
Because cancer detection rates are affected by other factors,
a logistic model was used, adjusting by radiology unit, initial
and successive screening, and age. Overall, the adjusted OR of
detection of cancer or interval cancer remained unchanged
throughout the period. However, the odds of DCIS detection
were higher in the FFDM periods than in the SFM periods. To
date, no other studies have adjusted the risk by time trends; a
recent Norwegian study found that the risk of DCIS detection
was increased during the whole FFDM period, but no
Fig. 3 Rates of overall screen-
detected cancer, invasive cancer
and ductal carcinoma in situ
































































































































































Fig. 4 Logistic regression models for the detection of screen-detected
cancer, interval cancer, ductal carcinoma in situ (DCIS) and invasive cancer.
Themodels are adjusted by radiology unit, age (continuous) andwhether the
diagnosis was established at the initial or successive screenings. a Screen-
detected cancers, b interval cancers, c ductal carcinoma in situ (DCIS), d
invasive cancers. The reference category is the first screen-film mammog-
raphy period. The black points and the vertical lines represent the odds ratio
(OR) and the corresponding 95 % confidence intervals, respectively
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increased risk was found for screen-detected cancers overall,
invasive cancers or interval cancers [6].
This study has some limitations. Although the study period
is one of the longest ever analysed, the number of DCIS does
not allow exploration of trends in tumoral grade during the
digital period. We had no information on interval cancer
subtypes, and therefore we could not assess the behaviour of
false negatives before and after the shift to digital technology.
The main strength of the current work is the long study
period, with more than 6 years of complete digitalization. This
allowed us to study trends over time, beyond the first digital
period after the transition. Because of the wide variability
observed in the performance indicators of screening programs,
both within and between countries, cross-sectional observa-
tions cannot reflect the real impact of one intervention. Dif-
ferences observed in a given screening participation (screen-
ing round) may be compensated for in subsequent screening
participations. After confirming that the direction of our find-
ings was not modified, we excluded the first screening round
of both the radiology units, both of which used SFM, which
reduced the sample size in the analogical period but ensured
that the indicators in the SFM period were not confounded by
the prevalence peak after the implementation of screening, or
by the larger tumour sizes found in the first screening round
[24]. We included the first 3 months after the switch to digital
mammography because it did not modify the outcomes.
In conclusion, this study supports the idea that the increase
in DCIS detection observed with the introduction of FFDM is
partly due to an improvement in early diagnosis and confirms
the reduction in the false-positive rate with no increase
in the interval cancer rate. In view of the current re-
sults, which are supported by those from previous stud-
ies performed in different countries, the use of digital
technology should not be seen as a threat that increases
the negative effects of screening through overdiagnosis.
Future recommendations on screening performance and
quality standards should be updated with information
from screening settings using this technology.
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